CONTINUE TO SITE
OR WAIT null SECS
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
Generic versions of oxybutynin gain approval for OAB
The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder.
The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder. Mylan Laboratories received final approval for 5- and 10-mg extended-release tablets, and IMPAX Laboratories received approval for 15-mg extended-release tablets. Both companies said the products would be launched immediately.